PFE · 8-K · 20260804PR000094
Product Demand Trends
PFIZER INC · 2026-08-04 · Importance 42 · Surprise 40 · From source text
Pfizer’s launched and acquired products grew 18% operationally year over year in the second quarter of 2026. Excluding Comirnaty and Paxlovid, company revenue increased 5% operationally. Eliquis revenue rose 19% globally on higher demand and favorable U.S. pricing and channel mix, while Padcev increased 23% on first-line urothelial-cancer market-share gains and launch uptake. Vyndaqel grew 8% on strong international demand, continued patient diagnosis and improved access, and Lorbrena increased 37% on higher patient share in first-line ALK-positive metastatic non-small cell lung cancer in the U.S., China and other international markets.
Key facts
- Abrysvo revenues in Second-Quarter 2026: $208 million, up 46% (or 43% operational) versus 2025; U.S. $55 million, down 46%; International $153 million source
- Eliquis global operational growth: up 19% in Q2 2026 source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +0.4% | Abrysvo revenues in Second-Quarter 2026: $208 million, up 46% (or 43% operational) versus 2025; U.S. $55 million, down 46%; International… |